Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2025-11-24 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
对外投资管理制度（2025年11月）
Governance Information Classification · 95% confidence The document is titled '对外投资管理制度' which translates to 'External Investment Management System' and is a detailed internal policy document of the company regarding procedures, principles, approval processes, and management of external investments. It references relevant laws and company governance documents but does not contain financial statements, earnings data, or regulatory filings. It is a governance or management policy document rather than a financial report or announcement. It is not a report publication announcement or a certification. The document is about internal management rules and procedures for external investments, which fits best under Governance Information (CGR).
2025-11-24 Chinese
控股子公司管理制度（2025年11月）
Governance Information Classification · 95% confidence The document is titled '控股子公司管理制度' which translates to 'Management System for Controlling Subsidiaries' of 健帆生物科技集团股份有限公司. It is a detailed internal governance and management policy document outlining rules and procedures for managing controlling subsidiaries, including chapters on general principles, operational norms, personnel management, financial management, investment management, information management, audit supervision, and assessment and rewards. It references relevant laws and regulations but does not contain financial statements, earnings data, or shareholder meeting materials. It is not an announcement or a report of financial results, nor a regulatory filing or certification. It is a governance-related internal policy document detailing company internal rules and governance practices. Therefore, the most appropriate classification is Governance Information (CGR). The document length (5164 characters) and content support this classification with high confidence.
2025-11-24 Chinese
内幕信息知情人登记制度（2025年11月）
Governance Information Classification · 95% confidence The document is titled '内幕信息知情人登记制度' which translates to 'Insider Information Insider Registration System' and is issued by 健帆生物科技集团股份有限公司. It details the company's internal policies and procedures for managing insider information, including definitions, scope, registration, confidentiality, and responsibilities. It references relevant laws and regulatory bodies such as the China Securities Regulatory Commission and Shenzhen Stock Exchange. The document is a governance-related internal policy document rather than a financial report, announcement, or regulatory filing. It does not contain financial data, earnings, or audit information. It is not an announcement of a report but a detailed governance policy document. Therefore, the most appropriate classification is Governance Information (CGR). The document length (7178 characters) supports it being a full policy document rather than a brief announcement or certification.
2025-11-24 Chinese
募集资金管理制度（2025年11月）
Governance Information Classification · 95% confidence The document is titled '募集资金管理制度' which translates to 'Fundraising Capital Management System' and is issued by 健帆生物科技集团股份有限公司. It is a detailed internal policy document outlining the management, use, supervision, and responsibilities related to the company's raised funds (募集资金). The content includes regulatory references, procedures for managing raised funds, usage restrictions, supervisory roles, and accountability measures. It is not a financial report, earnings release, or announcement of voting results. It is a governance-related document detailing internal rules and procedures for managing capital raised by the company. Therefore, it fits best under Governance Information (CGR). The document length (8245 characters) and detailed procedural content support this classification with high confidence.
2025-11-24 Chinese
内部审计工作制度（2025年11月）
Governance Information Classification · 95% confidence The document is titled '内部审计工作制度' (Internal Audit Work System) of 健帆生物科技集团股份有限公司 and is a detailed internal audit policy document. It outlines the internal audit framework, responsibilities, procedures, scope, and authority within the company. It references relevant laws and regulations, internal control evaluation, audit committee roles, and audit reporting processes. The document is a comprehensive internal governance and audit policy manual rather than a financial report, earnings release, or announcement. It does not contain financial statements or results but focuses on internal audit rules and governance. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-11-24 Chinese
公司章程（2025年11月）
Governance Information Classification · 100% confidence The document is titled as the Articles of Association (章程) of 健帆生物科技集团股份有限公司 dated November 2025. It contains detailed corporate governance rules, shareholder rights, board structure, share issuance, share transfer, and other organizational and operational regulations. It references Chinese company law, securities law, and regulatory requirements. The content is a comprehensive governance document outlining the company's internal rules and shareholder meeting procedures. It is not a financial report, earnings release, or announcement but a governance charter. Therefore, it fits the category of Governance Information (CGR). The document length is substantial (15,000 characters), indicating it is the full text of the governance document, not a brief announcement or summary.
2025-11-24 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.